Benefits of Model-based Drug Development: A Rigorous, Planned Case Study

Model-based drug development (MBDD) is useful to make better quantitative decisions within drug development. However, rigorous evaluation of the benefits has been scarce in the literature. In this study, we take a completed development program, retrospectively repeat it in a virtual setting using MBDD methodologies, and compare it to the traditional drug development process. The conclusion is that the use of MBDD could have facilitated more efficient use of resources.

[1]  M. Karlsson,et al.  Randomized exposure-controlled trials; impact of randomization and analysis strategies. , 2007, British journal of clinical pharmacology.

[2]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[3]  J. DiMasi,et al.  Drug development costs when financial risk is measured using the Fama-French three-factor model. , 2009, Health economics.

[4]  R. Reeve,et al.  Pharmacodynamic Models: Parameterizing the Hill Equation, Michaelis-Menten, the Logistic Curve, and Relationships Among These Models , 2013, Journal of biopharmaceutical statistics.

[5]  The randomized concentration-controlled trial:mathematical definitions, a dose-adjusting algorithm, and sample size efficiency , 1996 .

[6]  V. Anisimov.  Using Mixed Poisson Models in Patient Recruitment in Multicentre Clinical Trials , 2008 .

[7]  L. Endrenyi,et al.  Comparative efficiencies of randomized concentration‐ and dose‐controlled clinical trials , 1994, Clinical pharmacology and therapeutics.

[8]  M. Walton.  The Deming management method , 1986 .

[9]  L. Lesko,et al.  Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.

[10]  Jean‐Paul Squifflet,et al.  The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation , 1998, Clinical pharmacology and therapeutics.

[11]  Modelling and Predicting Patient Recruitment in Multi-centre Clinical Trials , 2011 .

[12]  Patrick Poulin,et al.  Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. , 2003, Toxicology letters.

[13]  V. Anisimov.  Predictive Modelling of Recruitment and Drug Supply in Multicenter Clinical Trials , 2009 .

[14]  L Aarons,et al.  Role of modelling and simulation in Phase I drug development. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[16]  Vikram Sinha,et al.  Model-Based Drug Development: The Road to Quantitative Pharmacology , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  Malcolm Rowland,et al.  Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2004, Pharmaceutical Research.